Protein Crystallization Market (2026 - 2033)

Protein Crystallization Market Summary

The global protein crystallization market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 2.3 billion in 2033, at a CAGR of 9.1% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 36.0% in 2025. Protein crystallization is the method of obtaining a protein crystal by adding precipitating agents and monitoring conditions such as pH, temperature, and ionic strength of the solution.

One of the most important applications of crystallization is supporting structural biology investigations using X-ray diffraction. This process helps researchers to visualize the 3-dimensional structures of proteins. In addition, crystallization is an effective method for producing pure, contamination-free proteins, thus offering an alternative means of separation and purification to preparative chromatography. Hence, the method has a variety of applications in industries, including drug development, purification & separation, scale-up, formulation, medicinal chemistry, and drug delivery.

Several emerging players in the proteomics space are receiving funding and investments to advance proteomics applications. In addition, several investments under government initiatives are increasing the adoption of protein crystallization in proteomics research and development. For instance, in December 2025, the University of Arkansas for Medical Sciences (UAMS) received a five-year, USD 10.5 million grant from the National Institutes of Health (NIH) to develop biomarkers for all human diseases, including cancer, through the IDeA National Resource for Quantitative Proteomics. Thus, rising funding for proteomics research is expected to boost the market during the forecast period.

Moreover, in recent years, an increasing number of individuals have been using protein-based drugs owing to their advantages, such as low toxicity, high potency & specificity, and high tolerance in the human body. In addition, key players in the market are entering into partnerships and collaborations to develop protein-based therapeutics at more affordable costs for patients. For instance, in June 2026, Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, announced it had signed a multi-target discovery collaboration and license agreement with Merck. The agreement combines Protillion’s proprietary platform with Merck’s global expertise in the discovery of novel therapeutic candidates. Thus, such initiatives are anticipated to boost the adoption of crystallization methods in the study period.

Furthermore, technological advancements in crystallization techniques, such as cell-free protein crystallization methods, are anticipated to offer lucrative opportunities for the market during the estimated timeframe. The technique represents a major advance in structural biology by enabling analysis of unstable proteins that cannot be studied by other conventional methods. Such advancements help researchers develop novel, improved versions of protein crystals to treat various diseases, ranging from muscular dystrophy to cancer, thereby fueling the market. 

Market Dynamics

The protein crystallization market is experiencing significant growth, driven by the increasing demand for protein structure determination in drug discovery, structural biology, and biologics development. The rising adoption of structure-based drug discovery, growing research activities in proteomics and genomics, and expanding development of targeted therapies and protein-based therapeutics are fueling market expansion. In addition, advancements in automated crystallization platforms, high-throughput screening technologies, microfluidics, and AI-assisted protein structure analysis, coupled with increasing investments in life sciences research and precision medicine initiatives, are expected to further support market growth over the forecast period.

Analyst Perspective

The market is experiencing steady growth, driven by increasing structural biology research and the growing need for highly effective protein structures. Pharmaceutical and biotechnology companies largely use protein crystallization techniques to determine protein structure. As demand for high-quality protein crystals and advanced imaging, such as X-ray crystallography, continues to rise, companies that focus on product innovation, workflow automation, and application diversification will be well-positioned to capitalize on long-term growth opportunities.

Product Insights

The consumables segment held the largest market share of over 67.0% in 2025. Consumables include reagents & kits/screens, microplates, and other products to support the crystallization methods. Crystallization kits for proteins provide an efficient screening method for determining the optimal solubility conditions for protein crystallization. These kits also provide the reagents required for rapid screening to determine the appropriate condition for the crystallization of purified protein samples.

Several key players in the market are offering a wide range of consumables. For instance, Corning Incorporated offers Corning Next Generation CrystalEX Microplates for 96-well High-Throughput Sitting-Drop Protein Crystallization. Hence, advanced consumable offerings by the key players, coupled with recurring costs, are expected to boost the segment.

The software & services segment is anticipated to grow at the fastest CAGR over the forecast period. Software is used in crystallization experiment processes, from design and dispensing to analysis and image viewing. For instance, ROCK MAKER software offered by FORMULATRIX helps create multiple-screen experiments for one or more proteins in less than a minute. It also helps compare captured images and assigns scores.

Such software capabilities are likely to boost segment growth during the forecast period. Moreover, several players are offering protein crystallization services, thereby expected to fuel the segment growth. For instance, Creative Biolabs offers crystallization services including purification, biophysical characterization, crystallization screening & crystal optimization to accelerate research projects.

Technology Insights

The X-ray crystallography segment held the largest share of above 53.0% in 2025. X-ray crystallography is the most widely used technique for determining the structures of biological macromolecules and proteins. It involves crystallizing proteins, pummeling them with X-rays, and recreating their structure from the resulting tell-tale patterns of diffracted light.

The technology offers several advantages, such as a two-dimensional view that provides an indication of a protein's 3-D structure. In addition, X-ray crystallography is relatively simple and cost-effective, offers better diffraction, reduces radiation damage to crystals, and enables the safe storage, transport, and reuse of crystals. Such capabilities of the technology are boosting the segment. For instance, in June 2025, Flindr Therapeutics, a precision oncology company developing first-in-class small molecule inhibitors for cancer, and CrystalsFirst, a leader in structure-based drug discovery and target enablement, announced a strategic partnership to accelerate target enablement and drug discovery across Flindr’s oncology pipeline. By integrating cutting-edge crystallography and AI-driven molecular design, Flindr aims to fast-track additional first-in-class programs toward preclinical development.

The cryo-electron microscopy segment is projected to expand at the highest CAGR of approximately 12.0% during the forecast period. Compared with traditional technologies such as NMR and X-ray crystallography, cryo-electron microscopy has several benefits, including suitability for proteins and their complexes with large molecules, no requirement for crystals, reduced radiation damage, and preservation of the functional state and native activity of the samples, including post-translational modifications.

In addition, cryo-electron microscopy requires minimal sample, is suitable for structural analysis of membrane proteins such as GPCRs and their complexes, and can capture multiple conformational states in a single experiment. Hence, advantages associated with cryo-electron microscopy are expected to drive the segment during the study period.

End-user Insights

The pharmaceutical and biotechnology companies segment accounted for the highest revenue share, at approximately 68.0%, in 2025. Protein crystallization methods play two major roles in structural biology: in silico drug design and controlled drug discovery. In silico drug design and protein crystallography ascertain the 3-D structure of a molecule. The formation of protein crystals results in more accurate 3-D protein structures. These quality crystals can ultimately lead to a better understanding of biological function and enhanced drug design in pharmaceutical and biotechnology companies.

Furthermore, the pharmaceutical and biotechnology companies segment is also anticipated to expand at the fastest pace during the forecast period. The information gathered from 3D protein structures can be used to understand disease mechanisms, optimize pharmaceutical drug design, and identify drug targets. Transformative therapeutics developed using protein crystallography include the leukemia drug Gleevec and HIV protease inhibitors.

In addition, another potential application of the method is in biologics formulation, by reducing the viscosity of proteins in the crystalline form to enable higher concentrations of effective protein-based therapeutics. Such applications of protein crystallization in pharma & biotech companies are expected to significantly drive the segment.

Regional Insights

North America held the largest share of approximately 36.0% in the global market in 2025. This large share can be attributed to increased investments in private companies, government assistance, and favorable regulations. The region primarily focuses on research in drug discovery and protein structure prediction, thereby propelling market growth. The presence of innovators and key operating players has resulted in higher product penetration in the region.

For instance, in November 2024, Rigaku Corporation, a Rigaku Holdings Group company, opened the Rigaku BioScience Lab in Cambridge, Massachusetts, U.S. Rigaku has begun operating MoleQlyze at the Rigaku BioScience Lab. MoleQlyze incorporates a technology, developed by Rigaku, called electron density topography (EDT), which elucidates the structure and dynamic characteristics of biological macromolecules, including antibodies, protein complexes, and virus particles, in solution.

Asia Pacific Protein Crystallization Market Trends

The protein crystallization market in the Asia Pacific region is estimated to expand at the fastest CAGR of approximately 11.0% during 2026-2033. This high rate of progression can be attributed to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies such as China and India. This region's profitable expansion is also attributed to ongoing government support for the development of the pharmaceutical sector in developing countries. Moreover, ongoing research in cancer & infectious diseases is expected to drive significant market growth.

Key Protein Crystallization Company Insights

The protein crystallization industry features a range of global, regional, and local players, making it a competitive market. The world’s leading companies are using partnerships, collaborations, acquisitions, mergers, and agreements as strategies to withstand the intense competition and increase their market share. Protein Crystallization product manufacturers are investing heavily in product enhancements and new product development.

Key Protein Crystallization Companies

The following key companies have been profiled for this study on the protein crystallization market

• Rigaku Corporation 

• FORMULATRIX

• METTLER TOLEDO

• Corning Incorporated

• Greiner Bio-One International GmbH

• HAMPTON RESEARCH CORP

• Jena Bioscience GmbH

• Bruker

• Creative Proteomics

• Molecular Dimensions

Competitive Benchmarking

Recent Developments

• In October 2025, Pharmaron Beijing Co., Limited announced the acquisition of 82.54% equity interest of Biortus Biosciences Co., Ltd. and its affiliates. This acquisition was aimed at enhancing the company’s technological platform and service capabilities in structural biology, complex protein production, and analysis, and further strengthening its end-to-end, fully integrated, multi-modality services platform with a global footprint.

• In February 2026, Nuclera, the biotechnology company enabling rapid access to high-quality proteins, partnered with leadXpro, a specialist in structure-based drug discovery for membrane proteins, to bring together eProtein Discovery’s rapid multiplex membrane protein screening with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development.

Protein Crystallization Market Report Scope

Global Protein Crystallization Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global protein crystallization market report based on the product, technology, end user, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

    • Liquid Handling Instruments

    • Crystal Imaging Instruments

  • Consumables

    • Reagents & Kits/Screens

    • Micro Plates

    • Others

  • Software & Services

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • X-ray Crystallography

  • Cryo-electron Microscopy

  • NMR Spectroscopy

  • Others

• End-User Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical And Biotechnology Companies

  • Academic And Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The protein crystallization market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each protein crystallization segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations